Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma
Posted Date: May 15, 2019
- Investigator: Jordan Kharofa
- Type of Study: Drug
Standard treatment for esophageal adenocarcinoma is treatment with radiation therapy and the chemotherapy drugs paclitaxel and carboplatin. Afterwards, surgery is done to remove the esophagus. This study will test whether the addition of the drug tastuzumab to standard treatment can help prevent you
Criteria:
Eligible Patients Must Have Cancer Of The Esophagus
Keywords:
Esophageal Cancer, Esophagus, Gastrointestinal Can, Gi Cancer, R1010
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu